Want to see AMLX full AI Analyst Report?
Top Page
Amylyx Pharmaceuticals Inc
(NASDAQ:AMLX)
Select Model
Select Model
Rating:58Neutral
Price Target:
$18.00
▼(-1.96% Downside)
Action:Reiterated
Date:06/26/26
The score is held down primarily by sharply deteriorated fundamentals (revenue collapse to $0 in 2025/TTM, large ongoing losses, and heavy negative free cash flow). Offsetting factors include a low-debt balance sheet and strong current technical momentum, plus a relatively positive earnings-call outlook tied to the fully enrolled Phase III LUCIDITY trial and ongoing NDA preparation—though the upcoming Q3 2026 readout remains the central binary risk.
Positive Factors
Low leverage balance sheet
The company's balance sheet shows very low debt relative to equity, giving it financial flexibility to fund development and regulatory milestones without immediate refinancing. This durable low-leverage position reduces short-to-medium-term insolvency risk while clinical programs progress.
Negative Factors
Revenue collapse and commercial traction loss
The abrupt fall to zero reported revenue indicates a severe loss of product income and commercial traction. Without recurring product sales, the business fundamentally relies on clinical/regulatory outcomes and financing, increasing execution risk and making long‑term growth contingent on trial success and subsequent market uptake.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage balance sheet
The company's balance sheet shows very low debt relative to equity, giving it financial flexibility to fund development and regulatory milestones without immediate refinancing. This durable low-leverage position reduces short-to-medium-term insolvency risk while clinical programs progress.
Read all positive factors
Amylyx Pharmaceuticals Inc (AMLX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.89B
Dividend YieldN/A
Average Volume (3M)1.66M
Price to Earnings (P/E)―
Beta (1Y)1.50
Revenue GrowthN/A
EPS Growth51.42%
CountryUS
Employees136
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.48
Shares Outstanding111,186,320
10 Day Avg. Volume1,173,600
30 Day Avg. Volume1,659,734
Financial Highlights & Ratios
PEG Ratio0.12
Price to Book (P/B)3.74
Price to Sales (P/S)0.00
P/FCF Ratio-9.25
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$26.29Price Target Upside43.17% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-1.41
Revenue Forecast (FY)N/A
Amylyx Pharmaceuticals Inc Business Overview & Revenue Model
Company Description
Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, primarily focused on creating therapies for amyotrophic lateral sclerosis (ALS) and various other neurodegenerative conditions. A key asset in its developmental pipe...
How the Company Makes Money
null...
Amylyx Pharmaceuticals Inc Earnings Call Summary
Earnings Call Date:May 07, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Aug 06, 2026
Earnings Call Sentiment Positive
The call emphasized strong operational execution: pivotal Phase III LUCIDITY enrollment completed and on track for a Q3 2026 top-line readout, active NDA preparation, clear commercial planning (including an EAP for up to 250 patients), and multiple pipeline programs advancing (AMX0318 IND-enabling work, AMX0035 longer-term data, AMX0114 cohort progress). Financially, while the company has a cash position of $279.8M with runway into 2028, cash declined ~11.7% year-over-year and operating expenses increased (total operating expenses +16% YoY; R&D +24.9% YoY), driven by development and milestone payments—risks remain tied to the upcoming LUCIDITY result and the need to convert clinical success into regulatory approval and commercial uptake.Positive Updates
Pivotal Phase III LUCIDITY Enrollment Complete and On Track
Randomized and dosed the last participant in late March; clear line of sight to complete the 16-week trial with top-line readout expected in Q3 2026. Study is powered at 90% and was designed to replicate prior positive trials (prior trials showed ~55% and 64% reductions in hypoglycemic events).
Negative Updates
Decrease in Cash Position Year-over-Year
Cash and marketable securities declined from $317.0M (prior comparable period) to $279.8M, a decrease of approximately $37.2M or ~11.7%, increasing reliance on execution of planned milestones to preserve runway.
Read all updates
Q1-2026 Updates
Positive
Negative
Pivotal Phase III LUCIDITY Enrollment Complete and On Track
Randomized and dosed the last participant in late March; clear line of sight to complete the 16-week trial with top-line readout expected in Q3 2026. Study is powered at 90% and was designed to replicate prior positive trials (prior trials showed ~55% and 64% reductions in hypoglycemic events).
Read all positive updates
Company Guidance
Management reiterated that avexitide’s pivotal Phase III LUCIDITY trial (90 mg once daily, 16‑week study; FDA‑agreed primary endpoint = composite of Level 2 [<54 mg/dL] and Level 3 hypoglycemic events) is fully enrolled, remains on track for a top‑line readout in Q3 2026, and that NDA preparations are underway with potential FDA approval and a commercial launch targeted in 2027; they also launched a U.S. expanded access program for up to 250 adults, estimate ~160,000 U.S. PBH patients after sleeve or Roux‑en‑Y surgery, and are building commercial and medical teams. Financials/guidance included $279.8M in cash and marketable securities (vs. $317M a year earlier) supporting a cash runway into 2028, Q1 operating expenses of $43.8M (up 16% year‑over‑year) with R&D $27.6M (vs. $22.1M) and SG&A $16.2M (vs. $15.7M), $6.1M non‑cash stock‑based comp (vs. $6.8M), and a $4M milestone paid to Gubra; other pipeline timelines noted: AMX0318 IND‑enabling work targeting a 2027 IND, AMX0035 week‑96 data planned for an upcoming meeting, and AMX0114 Cohort 2 fully enrolled with Cohort 1 biomarker data to be presented at ENCALS in June (LUCIDITY was powered ~90% and prior avexitide studies showed ~55% [PREVENT] and ~64% (90 mg) reductions, p=0.0031).Amylyx Pharmaceuticals Inc Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 87.37M | 380.79M | 22.23M | 0.00 |
| Gross Profit | -20.20M | -525.00K | 45.22M | 355.35M | 19.24M | 0.00 |
| EBITDA | -147.70M | -144.16M | -290.98M | 55.38M | -197.11M | -87.88M |
| Net Income | -150.11M | -144.74M | -301.74M | 49.27M | -198.38M | -87.93M |
Balance Sheet | ||||||
| Total Assets | 293.60M | 332.64M | 193.63M | 517.45M | 391.45M | 105.61M |
| Cash, Cash Equivalents and Short-Term Investments | 279.77M | 316.98M | 176.50M | 371.36M | 346.94M | 96.12M |
| Total Debt | 5.63M | 5.96M | 1.98M | 4.24M | 6.28M | 0.00 |
| Total Liabilities | 20.44M | 27.39M | 28.87M | 84.02M | 50.85M | 256.78M |
| Stockholders Equity | 273.16M | 305.26M | 164.76M | 433.43M | 340.61M | -151.17M |
Cash Flow | ||||||
| Free Cash Flow | -120.53M | -123.48M | -167.80M | 10.68M | -182.40M | -75.15M |
| Operating Cash Flow | -120.40M | -123.34M | -167.65M | 11.92M | -179.87M | -74.80M |
| Investing Cash Flow | 93.96M | 14.04M | 75.65M | 92.05M | -238.99M | -46.41M |
| Financing Cash Flow | 194.58M | 257.03M | 348.00K | 3.54M | 431.79M | 158.51M |
Amylyx Pharmaceuticals Inc Technical Analysis
Positive
18.36
Price Trends
15.48
Positive
15.43
Positive
14.57
Positive
Market Momentum
0.63
Positive
56.45
Neutral
40.42
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AMLX, the sentiment is Positive. The current price of 18.36 is above the 20-day moving average (MA) of 17.59, above the 50-day MA of 15.48, and above the 200-day MA of 14.57, indicating a bullish trend. The MACD of 0.63 indicates Positive momentum. The RSI at 56.45 is Neutral, neither overbought nor oversold. The STOCH value of 40.42 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AMLX.
Amylyx Pharmaceuticals Inc Risk Analysis
Amylyx Pharmaceuticals Inc disclosed 89 risk factors in its most recent earnings report. Amylyx Pharmaceuticals Inc reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Amylyx Pharmaceuticals Inc Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | $1.94B | 13.40 | 17.19% | ― | 20.71% | -5.53% | |
58 Neutral | $1.89B | -11.99 | -55.68% | ― | ― | 51.42% | |
58 Neutral | $2.31B | -5.37 | 123.57% | ― | 75.92% | -569.22% | |
55 Neutral | $5.21B | -960.00 | -1.78% | ― | -79.52% | -43.40% | |
52 Neutral | $2.35B | -10.79 | -67.40% | ― | ― | -5.22% | |
52 Neutral | $2.13B | -2.72 | -866.46% | ― | ― | 39.46% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
AMLX
Amylyx Pharmaceuticals Inc
17.75
9.41
112.83%
BCRX
BioCryst
9.29
0.68
7.90%
DNTH
Dianthus Therapeutics
105.60
85.20
417.65%
HRMY
Harmony Biosciences Holdings
33.77
-1.43
-4.06%
PHVS
Pharvaris
34.94
11.69
50.31%
BHVN
Biohaven Ltd.
15.44
1.39
9.89%
Amylyx Pharmaceuticals Inc Corporate Events
Executive/Board ChangesShareholder Meetings
Amylyx Shareholders Approve Directors, Auditor and Executive Pay
Positive
Jun 4, 2026
On June 4, 2026, Amylyx Pharmaceuticals, Inc. held its Annual Meeting of Stockholders, where investors elected George Mclean Milne Jr., Ph.D., and Paul Fonteyne as Class II directors for three-year terms ending at the 2029 annual meeting, reinforc...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.